Abstract
Recently, lncRNA DILC has been reported as a regulatory element in carcinogenesis of various tumors. Nevertheless, its impact on cancer immunity remains limited in breast cancer. The rationale of this study was to identify and correlate the impact of DILC and the PD-L1 inhibitor; Atezolizumab on the metastatic and oxidative function of PBMCs in tumor microenvironment (TME) of TNBC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
